Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any ataxia-telangiectasia-like disorder in which the cause of the disease is a mutation in the MRE11 gene.
Features include always present findings: Unsteady gait; and very common findings: Ataxia. 45 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 13 | Dystonia, Gait ataxia, Ataxia |
Eyes |
MRE11 encodes MRE11 double strand break repair nuclease (708 aa). Core component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis. Highest expression in Cells EBV-transformed lymphocytes (22.2 TPM) and Nerve Tibial (16.4 TPM).
Ataxia-telangiectasia-like disorder 1 is associated with mutations in the MRE11 gene on chromosome 11.
The MRE11 protein participates in MRN bound to shortened telomeres activates ATM and MRN recruits LIG3:XRCC1 to MMEJ sites pathways.
MRE11 is classified as a druggable target (Clinically Actionable, Dna Repair, and Kinase categories) with score 0.0.
Genetic testing for MRE11 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 1 very common feature, 20 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for ataxia-telangiectasia-like disorder 1.
4 publications have been identified in PubMed for ataxia-telangiectasia-like disorder 1. Research spans Basic Science / Preclinical (100%).
Westover KR (2026). [PMID: 41544707](https://pubmed.ncbi.nlm.nih.gov/41544707/). *J Biol Chem*. [Basic Science / Preclinical]
DeFoer MB (2025). [PMID: 40791546](https://pubmed.ncbi.nlm.nih.gov/40791546/). *bioRxiv*. [Basic Science / Preclinical]
DeFoer MB (2025). [PMID: 41075274](https://pubmed.ncbi.nlm.nih.gov/41075274/). *Hum Mol Genet*. [Basic Science / Preclinical]
Hartlerode AJ (2024). [PMID: 38888340](https://pubmed.ncbi.nlm.nih.gov/38888340/). *Hum Mol Genet*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 12:33 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
8
Gaze-evoked nystagmus, Horizontal jerk nystagmus, Oculomotor apraxia |
Muscles | 6 | Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia), Frequent falls |
Arms and legs | 1 | Lower limb spasticity |
Skin | 1 | Telangiectasia |
Growth and development | 1 | Short stature |
Hormones | 1 | Hypergonadotropic hypogonadism |
Bones and joints | 1 | Joint hypermobility |